Compare ONEW & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | CUE |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.2M | 177.0M |
| IPO Year | 2019 | 2017 |
| Metric | ONEW | CUE |
|---|---|---|
| Price | $9.39 | $18.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $13.33 | ★ $88.00 |
| AVG Volume (30 Days) | 77.3K | ★ 182.8K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.85 | N/A |
| P/E Ratio | $3.43 | ★ N/A |
| Revenue Growth | 5.62 | ★ 195.75 |
| 52 Week Low | $8.12 | $0.17 |
| 52 Week High | $17.35 | $45.50 |
| Indicator | ONEW | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 39.09 |
| Support Level | $8.98 | $18.20 |
| Resistance Level | $9.89 | $33.95 |
| Average True Range (ATR) | 0.53 | 2.60 |
| MACD | 0.07 | -0.25 |
| Stochastic Oscillator | 52.99 | 19.01 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.